Endocrinology
RSSArticles
-
Is the Combination of a GLP-1 Agonist and a SGLT2 Inhibitor Safe?
Adding a GLP-1 RA in a subgroup of type 2 diabetes patients on baseline SGLT2 inhibitor therapy revealed GLP-1 RA reduces major adverse cardiovascular event rates, regardless of baseline SGLT2 use.
-
Report from the 2023 American Diabetes Association Scientific Sessions
At the 2023 American Diabetes Association Scientific Sessions, experts presented key updates, advances, and best practices for patient care. A selection of presentations relevant to the internal medicine and primary care community is presented here.
-
Donislecel-jujn Allogenic Pancreatic Islet Cellular Suspension (Lantidra)
Lantidra can be prescribed to adults with type 1 diabetes who cannot approach target HbA1c levels because of current repeated episodes of severe hyperglycemia despite intensive diabetes management and education.
-
Anesthesiologists Call on Patients to Stop Taking Trendy Drug Before Surgery
Patients using a popular type 2 diabetes medication to lose weight might experience complications during elective procedures.
-
Sotagliflozin Tablets (Inpefa)
Sotagliflozin tablets can be prescribed to lower the risk of cardiovascular death, hospitalization for heart failure, and urgent heart failure visits among adults living with heart failure or type 2 diabetes mellitus, chronic kidney disease, and other cardiovascular risk factors.
-
Insulin Pump (Medtronic MiniMed 780G System)
The FDA has approved the first insulin pump with meal detection technology.
-
Insulin Resistance at the Blood-Brain Barrier in Alzheimer’s Disease
Alterations in cerebrovascular insulin receptor isoform levels were associated with Alzheimer’s disease pathology and caused deficits in insulin signaling at the level of the blood-brain barrier.
-
Bexagliflozin Tablets (Brenzavvy)
Bexagliflozin can be prescribed as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus.
-
Triglyceride-Lowering Therapy and Cardiovascular Events
Researchers studied pemafibrate vs. placebo in patients with type 2 diabetes, mild-to-moderate triglyceride elevations, and low levels of HDL and well-controlled LDL cholesterol. Despite a 31% reduction in triglyceride levels, there was no improvement in the risk of cardiovascular outcomes over a median follow-up of 3.4 years.
-
Teplizumab-mzwv Injection (Tzield)
Teplizumab can be prescribed to delay the onset of stage 3 type 1 diabetes in adults and pediatric patients age 8 years and older with stage 2 type 1 diabetes.